Chinese Pla General Hospital

The Boeing Company

Institute of Pharmacology and Toxicology Academy of Military Medical Sciences Pla China

Institute of Pharmacology and Toxicology Medical Sciences P.l.a. China

Long Long

Lili Wang

Song Li

Junhai Xiao

Wei Li

Wu Zhong

Xin Li

Zhibing Zheng

Guoliang Hu

Juan Liu

Kunlun He

Chunlei Liu

Jie Wang

Ruijun Li

Jie Tang

Zhongzhe Dong

Daniel Wei

Liu Weiqiang

Xinbo Zhou

Xingzhou Li

Yunde Xie

Xiaokui Wang

Hua Chen

Cynthia Anne Vandewall

Jie Bai

Ke Ma

Feifei Li

Ruiyuan Cao

Yiwei Liu

Paola Trapani

Peizhong Gao

Jiao Mo

Saverio Silli

Jialin Yuan

Jiyu Song

Haoming Luo

Yuchen Tan

Kudilaiti Kuerban

Shengqian Yang

Kunluu He

Ruijin Li

The present disclosure relates to a device for live animal transport, comprising: a bottom plate, comprising a liquid guide plate and a non-liquid guide plate, wherein the liquid guide plate has a first end and a second end opposite the first end; a plurality of support members, symmetrically provided at predetermined intervals on the bottom plate at the first end and the second end of the liquid guide plate, and extending in a first direction perpendicular to the bottom plate; a plurality of pillars, one end of each pillar being nested in a corresponding one support member, and the plurality of pillars being capable of telescoping in the first direction; a plurality of beams, extending in a second direction from the first end of the liquid guide plate to the second end of the liquid guide plate, each beam being supported by the other end of the pillar at the first end of the liquid guide plate and the other end of the pillar at the second end of the liquid guide plate; side plates, provided on the bottom plate and extending in the first direction around edges of the bottom plate; and a top portion, supported by the plurality of beams to cover an interior space formed by the bottom plate and the side plates, wherein the plurality of pillars are configured to telescope in the first direction so as to adjust a contour of the top portion

Device for live animal transport

An inflatable partition includes a flexible membrane, an inflatable frame, and a support member coupled to the inflatable frame. The inflatable frame extends along a periphery of the flexible membrane and has an inner edge adjacent to the flexible membrane and an outer edge. The inflatable frame further includes a sealing mechanism extending along at least a portion of the outer edge and the inflatable frame is inflatable between a first state and a second state. The inflatable partition includes a first structural member and a second structural member. Each of the first and second structural members is coupled to the inflatable frame and extends vertically from the upper portion to the bottom portion of the inflatable frame and the first and second structural members define an opening in the inflatable partition.

Inflatable partition

The present invention pertains to the field of pharmaceutical chemicals, and relates to a substituted acethydrazide derivative, preparation method and use thereof; preferably, relates to a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof can effectively inhibit proline hydroxylase, stabilize HIF-&#x3b1;, particularly HIF-1&#x3b1;, and has potency in the manufacture of a medicament for treatment and/or prophylaxis and/or adjuvant therapy of anemia, acute ischemic reperfusion injury. 

Substituted acethydrazide derivative, preparation method and use thereof

The present invention provides a cell model and a method for screening c-Fms tyrosine kinase inhibitors. Specifically, the present invention provides a cell that expresses macrophage colony stimulating factor receptor and STAT1 protein simultaneously. The present invention further provides a method for screening c-Fms tyrosine kinase inhibitors, a method for evaluating the inhibiting activity of a compound or a composition against c-Fms tyrosine kinase, and use of the cell in screening c-Fms tyrosine kinase inhibitors. The cell model established in the present invention is sensitive, highly effective and reliable, and can be used in high-throughput screening and/or high-content screening of c-Fms tyrosine kinase inhibitors.

Cell model and method for screening c-Fms kinase inhibitors

The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis. 

Acrylamide compounds and use thereof for inhibiting apoptosis

A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis. 

Urea compounds and use thereof for inhibiting apoptosis

The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof; to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent; and also to use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, or preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, or preventing or treating a disease or disorder associated with cardiomyocyte apoptosis. 

Hexenone compounds and medical use thereof

The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosis.

(2E)-3-phenyl-N-[2,2,2-Trifluoro-1-[[8-quinolineamino)thiomethyl]amino]ethyl]-2-acrylamide and pharmaceutical uses thereof

Growing community of inventors

Beijing, China

Long Long